Efficacy of administering Streptococcus salivarius K12 as a powder formula in preventing respiratory infections in infants

Abstract

The purpose of this study was to evaluate the efficacy and safety of Bactoblis® as a powder (sachets), containing Streptococcus salivarius K12 (minimum 1 billion CFU/sachet) for the prevention of respiratory diseases in young children. This open-label, single-centre, randomized, controlled clinical study was conducted between February 2019 and December 2019 at a Children’s Clinical Hospital belonging to the Department of Pediatrics of the Ukrainian Medical and Dental Academy. \nOf the 62 children aged six months to two years enrolled, 32 children received a Bactoblis® sachet once daily for 30 days. The children who did not receive Bactoblis® sachets (n=30) served as the control group. \nThe efficacy of prophylactic administration of Bactoblis® sachets was evaluated in terms of a reduction in the incidence of acute respiratory viral infection (ARVI) episodes, the presence of bacterial complications after a respiratory infection, a need for antibacterial agents and antipyretics and the frequency of visits to an otorhinolaryngologist during the 30-day treatment period and within 90 days of follow-up. \nChildren treated with Bactoblis® sachets had a significant reduction in the incidence of ARVI episodes compared to those in the control group (p